$JAGX News

Last published 5d ago

5d agoJAGXJaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of StockholdersACCESS NewswireJaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's November 6, 2026 Special Meeting of Stockholders (the "Special Meeting"). Six proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating t ...
1w agoJAGXCSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)ACCESS NewswireCompany remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease and short bowel syndrome for crofelemer powder for oral
3w agoJAGXJaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy DisorderACCESS NewswireMutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion disease and short bowel syndrome , for which crofelemer has demonstrated benefit in
4w agoJAGXJaguar Health Provides Update Regarding Special Stock DividendACCESS NewswireDividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternativesJaguar's rare disease intestinal failure development program for microvillus inclusion
4w agoJAGXPositive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's CrofelemerACCESS NewswireCompany remains sharply focused on its ongoing rare disease intestinal failure global development program for SBS-IF and microvillus inclusion disease for crofelemer powder for oral solution, targeting a mid-2027
4w agoJAGXReminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock DividendACCESS NewswireDividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternativesJaguar's rare disease intestinal failure development program for microvillus inclusion
1mo agoJAGXNapo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu DhabiACCESS NewswireCompany remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease and short bowel syndrome for crofelemer powder for oral solution,
1mo agoJAGXJaguar Health Announces a Special Stock DividendACCESS NewswireDividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives SAN FRANCISCO, CA / ACCESS Newswire / October 2, 2026 / Jaguar Health, Inc.
1mo agoJAGXPreliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology MeetingACCESS NewswireCompany remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease and SBS-IF for crofelemer powder for oral solution, targeting an NDA
1mo agoJAGXJaguar Health Receives Fee Waivers from FDAACCESS NewswireCompany remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease and SBS for crofelemer powder for oral solution, targeting an NDA filing
1mo agoJAGXJaguar Health, Inc. Announces Reverse Stock SplitACCESS NewswireReverse split approved at April 2026 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on September 17, 2026 Reverse split approved at April 2026 Special
2mo agoJAGXAll Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)ACCESS NewswireContinuation of treatment with blinded doses of crofelemer in the extension phase of the trial will support company's plans to file an NDA in mid-2027 for MVID, an ultrarare pediatric disease Continuation of
2mo agoJAGXNow Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in DogsACCESS NewswireNeonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance
2mo agoJAGXAdditional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)ACCESS NewswireJaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support for pediatric and adult rare IF diseases, including microvillus inclusion
2mo agoJAGXCommercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in DogsACCESS NewswireNeonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance
2mo agoJAGXJaguar Health Reports Second Quarter 2026 FinancialsACCESS NewswireCompany remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results
2mo agoJAGXJaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate UpdatesACCESS NewswireCompany plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / August 18, 2026 / Jaguar Health, Inc. today announced
3mo agoJAGXJaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1ACCESS NewswireAs announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two commercialized
3mo agoJAGXJaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm DogACCESS NewswireNeonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance
3mo agoJAGXAdditional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)ACCESS NewswireJaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support for rare IF diseases, including MVID SAN FRANCISCO, CA / ACCESS Newswire /
4mo agoJAGXPresentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)ACCESS NewswireCompany remains sharply focused on its ongoing global development program for crofelemer for rare IF diseasesNear-term milestones for IF program buttressed by continuing groundbreaking results of study, which
4mo agoJAGXJaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock DividendACCESS NewswireCompany remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure diseasesReminder: Two crofelemer presentations in pediatric intestinal failure patients with
4mo agoJAGXJaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in DogsACCESS NewswireJaguar's recently completed pivotal effectiveness study of crofelemer for the treatment of CID in dogs demonstrates positive, statistically significant results SAN FRANCISCO, CA / ACCESS Newswire / June 23, 2026 /
4mo agoJAGXJaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure ProgramACCESS NewswireReminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide updates on company's crofelemer development program for rare intestinal
4mo agoJAGXMagdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain PreventionACCESS NewswireWhole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / June 18, 2026 / Jaguar Health, Inc. today
5mo agoJAGXJaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure DiseasesACCESS NewswireClick here to register for eventTo access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, click hereReminder: Two crofelemer presentations
5mo agoJAGXJaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of StockholdersACCESS NewswireLisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 8, 2026 / Jaguar Health, Inc.
5mo agoJAGXJaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal DisordersACCESS NewswireCrofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation, is being
5mo agoJAGXJaguar Health Compliant with Nasdaq Bid Price RuleACCESS NewswireJAGX's securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. today announced that on May 26, 2026, the
5mo agoJAGXJaguar Health Reports First Quarter 2026 FinancialsACCESS NewswireNet revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi® and Canalevia®-CA1Company continues its focus on crofelemer
5mo agoJAGXJaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor ConferenceACCESS NewswireClick here to register for Jaguar's May 26 webcast; Click here to register for May 28 virtual presentation at Lytham Partners ConferenceCompany plans to file its Earnings Report on May 20, 2026 on Form 10-Q for the
5mo agoJAGXJaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral CrofelemerACCESS NewswireFirst MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer as adjunctive
6mo agoJAGXJaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price RuleACCESS NewswireSAN FRANCISCO, CA / ACCESS Newswire / May 8, 2026 / Jaguar Health, Inc. today provided an update on the status of the Company's listing on The Nasdaq Stock Market . On
6mo agoJAGXJaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)ACCESS NewswirePediatric patients with Intestinal Failure due to MVID, an ultrarare congenital disorder with lethal natural history, that has no available therapies and needs lifelong total Parenteral Support , could benefit
6mo agoJAGXJaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut HealthACCESS NewswireNeonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool formation, gut hydration, and bowel
6mo agoJAGXJaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in DogsACCESS NewswireCompany Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2026 / Jaguar Health, Inc. today announced topline results
6mo agoJAGXJaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock SplitACCESS NewswireReverse split approved at April 2026 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on April 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / April 27, 2026 /
6mo agoJAGXJaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)ACCESS NewswireIntestinal Failure occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease and/or short bowel syndrome Jaguar has received orphan drug designations for MVID & SBS
6mo agoJAGXJaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of StockholdersACCESS NewswireSAN FRANCISCO, CA / ACCESS Newswire / April 20, 2026 / Jaguar Health, Inc. today announced the voting results of the Company's Special Meeting of Stockholders held on April 20,
7mo agoJAGXArtificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) ProgramsACCESS NewswireGlobal Market for Short Bowel Syndrome, Including Intestinal Failure , Estimated to Reach $8.0 Billion by 20331AI data mining of real world clinical and symptom manifestation is beneficial in the development of
7mo agoJAGXReminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company UpdatesACCESS NewswireClick here to registerSAN FRANCISCO, CA / ACCESS Newswire / April 9, 2026 / Jaguar Health, Inc.Participation Instructions for WebcastWhen: Friday, April 10, 2026 at 8:30 a.m. EasternParticipant Registration
7mo agoJAGXJaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in DogsACCESS NewswireTopline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea in dogs receiving neratinib - a targeted tyrosine kinase
7mo agoJAGXJaguar Health Reports 2025 FinancialsACCESS NewswireNet revenue increase of 5% in Q4 2025 vs. Q3 2025Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and
7mo agoJAGXJaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI CongressACCESS NewswireJaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure indications; all patients with microvillus inclusion disease suffer from IF, as
7mo agoJAGXFDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)ACCESS NewswireMVID has a lethal natural history requiring life-sustaining parenteral support , which includes total parenteral nutrition , which is associated with significant toxicities; PS reduction could potentially reduce
8mo agoJAGXJaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term CatalystsACCESS NewswireSAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, March 12, 2026 at
8mo agoJAGXJaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing WarrantsACCESS NewswireStrengthening balance sheet and capitalization is a key Jaguar priorityCompany continues its sharp, strategic focus on global development program for crofelemer for rare-disease intestinal failure indicationsSAN
8mo agoJAGXJaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1ACCESS NewswireAs announced, Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two
8mo agoJAGXReminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock DividendACCESS NewswireDividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debtSAN FRANCISCO, CALIFORNIA / ACCESS Newswire / March 2, 2026 / Jaguar Health, Inc.
8mo agoJAGXJaguar Health Announces a Special One-time Stock DividendACCESS NewswireDividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debtSAN FRANCISCO, CA / ACCESS Newswire / February 18, 2026 / Jaguar Health, Inc. ("Jaguar"